SEC EDGARAUG 251 min read$CBLL

Foehr David sold $44K of CBLL

Foehr David (Senior VP, Finance and PAO) sold 1,852 shares of Ceribell, Inc. (CBLL) at an average of $23.99 ($23.95–$24.02) across 2 trades over 2026-08-21 to 2026-08-24 under a Rule 10b5-1 trading plan.

Original reporting

SEC EDGAR · Foehr David

Published Aug 25, 2026, 11:27 PM UTC

Analysis

alphai AI DeskAI-generated

Added to alphai Aug 25, 2026, 11:32 PM UTC. Informational, not investment advice.

How this was made

alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About alphai AI Desk Scoring methodology Report an issue

alphai market briefInsider activity

Primary signal

$CBLL

Neutral

high confidence

Mentioned

$CBLL

Relevance

2/10

alphai data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$CBLLNeutralLow

Why it matters

The transaction is a routine insider sell with limited market impact.

Market read

Small insider sale; unlikely to move the stock.

What to watch

Potential upcoming corporate actions or financing needs not disclosed.

Relevance 2/10Novelty 3/10Timing: post‑filing 2026‑08‑25

Background

Form 4 filing from Ceribell, Inc. (CBLL) reporting an insider sale under a 10b5‑1 plan.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$CBLLNeutralHigh confidence

Context

Senior VP of Finance sold 1,852 shares for $44,424.91 via a 10b5‑1 plan, reducing his stake to 35,899 shares.

Expected impact

Likely negligible impact on CBLL price.

Evidence & confidence

The sale size is small relative to market cap and was pre‑arranged, so market reaction is expected to be minimal.

Market effects

Sector

No material effect on the medical‑device sector.

Regional

None.

Global

None.

Counterpoint

What could challenge this read

If the insider is signaling concerns, a modest short could be considered, but evidence is weak.

Key entities

company
Ceribell, Inc.
NASDAQ‑listed medical‑device firm.
insider
David Foehr
Senior Vice President, Finance and PAO.

Read at source ← All news

AUG 15

$LNTHMed

Weekly Buzz: LNTH, CBLL Win FDA Nod; AURA Cuts Jobs; TDY Buys VREX; CGEM, DFTX Meet Trial Goals

Biopharma roundup reported FDA/EC approvals and trial updates for Lantheus (LNTH) TAUKLARIFY, Ceribell (CBLL) AI EEG algorithms, Labcorp (LH) PGDx CDx, and EU/UK approvals for Galderma (GDERF) Restylane Shaype and Rhythm (RYTM) IMCIVREE. GRAIL (GRAL) faces an FDA panel on Sept. 23. Teledyne (TDY) to buy Varex (VREX) for about $1.1B; Aura (AURA) cut 20% staff.

rttnews.com7 min

AUG 10

$CBLLHigh

Ceribell, Inc. (CBLL): Results of Operations and Financial Condition

Ceribell, Inc. (CBLL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Ceribell Reports Second Quarter 2026 Financial Results Sunnyvale, Calif. – August 10, 2026 – CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today repor

SEC EDGAR 8-K6 min

AUG 10

$CBLLMedAI 8/10

Ceribell Secures FDA Clearance For Advanced EEG AI Enhancements

Ceribell (CBLL) said the U.S. FDA granted 510(k) clearance for two AI enhancements in its cloud Neurology Portal: epileptiform abnormality detection and artifact reduction. The company says the updates improve EEG signal interpretation and reduce review time. CBLL shares closed Aug. 7, 2026 at $18.81, up 3.07%.

rttnews.com4 min

AUG 3

$CBLLMedAI 8/10

CeriBell stock rises after securing Medicare payment approval

CeriBell Inc. (NASDAQ:CBLL) shares rose about 3% after CMS approved a New Technology Add-on Payment for its Delirium Monitor System. The NTAP allows up to $2,171 per eligible Medicare patient case, starting Oct. 1, 2026, following FDA 510(k) clearance in Dec. 2025.

investing.com3 min

MAY 26

$CBLLMed

Manni Joseph S. sold $25K of CBLL

Manni Joseph S. (Chief Revenue Officer) sold 1,378 shares of Ceribell, Inc. (CBLL) at $18.00 on 2026-05-21.

SEC EDGAR2 min

SEP 4

$ILMNMedAI 8/10

Meister Keith A. sold $57.2M of ILMN (indirect holdings)

Meister Keith A. sold 263,560 indirectly-held shares of ILLUMINA, INC. (ILMN) at an average of $217.03 ($213.20–$221.55, $57.20M total) across 12 trades over 2026-09-02 to 2026-09-04.

SEC EDGAR1 min